Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBT Margin (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of EBT Margin data on record, last reported at 3005.85% in Q4 2025.

  • For Q4 2025, EBT Margin fell 300391.0% year-over-year to 3005.85%; the TTM value through Dec 2025 reached 561.74%, down 59329.0%, while the annual FY2025 figure was 561.74%, 59329.0% down from the prior year.
  • EBT Margin reached 3005.85% in Q4 2025 per TRDA's latest filing, down from 2693.93% in the prior quarter.
  • Across five years, EBT Margin topped out at 61.03% in Q2 2024 and bottomed at 3005.85% in Q4 2025.
  • Average EBT Margin over 3 years is 665.03%, with a median of 39.43% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 12752bps in 2024, then crashed -300391bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 21.98% in 2023, then tumbled by -109bps to 1.94% in 2024, then crashed by -155166bps to 3005.85% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 3005.85% in Q4 2025, 2693.93% in Q3 2025, and 2201.28% in Q2 2025.